盆腔疼痛的妇科内分泌治疗

目的研究盆腔疼痛的治疗。方法针对某医院124例盆腔疼痛的患者进行治疗效果探讨。结果 124例患者有42例患者痊愈,66例患者显效,其余无效,疗效显著。结论以抑制患者疼痛症状为目的,有效提高盆腔疼痛患者的生活质量。     

妇科常见内分泌疾病及其所致不孕的诊疗

受到环境污染及生活压力的影响,内分泌失调患者不断增加,尤其对育龄期妇女而言,如内分泌疾病严重往往导致不孕。鉴于本文对妇科常见内分泌疾病进行探讨,并提出诊疗建议,以期为由内分泌原因导致不孕的治疗提供参考。     

妇科内分泌失调的临床治疗体会

目的:分析妇科内分泌失调的临床治疗效果.方法:选取94例妇科内分泌失调患者作为研究对象,根据是否采取综合性疗法进行分组;对照组45例,采取单纯药物治疗;观察组49例,采取综合性疗法,在对照组治疗的基础上,给予心理干预、健康宣教、饮食指导、生活方式指导、中医辨证论治;对比两组患者治疗前后的卵泡生成激素(FSH)、雌二醇(E2)表达水平,综合评价患者的临床治疗效果,并作对比分析.结果:治疗后,观察组患者的FSH、E2表达水平均较对照组明显提高,经T检验,差异具有统计学意义(P＜0.05);观察组临床治疗总有效率为91.84％,大于对照组的75.56％,经x2检验,差异具有统计学意义(P＜ 0.05).结论:综合性疗法治疗妇科内分泌失调的临床治疗效果确切,对于提高FSH、E2表达水平,改善预后均具有积极作用.     

芳香化酶抑制剂在妇科内分泌治疗中的临床价值分析

目的：探讨分析芳香化酶抑制剂在妇科内分泌治疗中的临床效果。方法：选取我院2012年11月～2013年11月收治的68例妇科内分泌病症患者为研究对象,随机分为观察组及对照组各34例,分别给予芳香化酶抑制剂（来曲唑）及米非司酮,观察两组患者临床治疗效果。结果：观察组患者总有效率为94.1%,对照组患者总有效率为79.4%,对比差异显著具有统计学意义（P＜0.05）。结论：芳香化酶抑制剂在妇科内分泌治疗中的临床效果较显著,能有效改善患者身体状况,提高患者生活质量。     

孕激素类药物在妇科内分泌疾病中的应用价值及不良反应分析

目的:研究分析在妇科内分泌疾病的治疗中采用孕激素类药物的治疗效果.方法:回顾我院诊治的280例妇科病患者资料进行分析,对于用药干预后孕激素类药物的临床治疗效果进行评估.结果:本次研究中的患者不良反应发生率为10.71％.结论:在多种妇科内分泌疾病的治疗中采用孕激素类药物进行治疗,治疗效果显著,且不良反应少.     

盐酸吡哆醇在妇科内分泌失调中的应用

<正> 功能性月经失调是妇科极为常见的疾病,临床治疗方法很多,但单纯用大量盐酸吡哆醇(V-B~6)进行治疗。国内外报道不多。我们从1980年以来,单纯口服大剂量V-B_6对503例患者进行了治疗,获得满意疗效。现报道如下: 临床资料一、一般资料:本组503例,青春期(包括婚     

妇科内分泌失调的临床治疗效果观察

目的观察妇科内分泌失调的临床治疗效果,明确最佳的治疗方案。方法选取我院妇科在2013年6月至2015年5月诊治的部分内分泌失调患者作为研究对象,共66例,对患者进行编号,1～66号,其中奇数号为对照组,33例,单纯采用中医治疗,偶数号为观察组,采用中西医结合方案治疗。结果治疗前患者FSH、E2相比无显著差异,治疗后患者FSH、E_2均有所变化,且观察组改善更加明显(P <0.05),有统计学意义;观察组治疗有效率为96.97%,对照组治疗有效率为75.76%,两组对比有统计学意义(χ~2=9.8543,P <0.05)。结论对妇科内分泌患者采用中医学结合的方案进行治疗可以显著提高治疗的临床效果,具有重要的临床应用价值。     

芳香化酶抑制剂在妇科内分泌治疗中的应用效果观察

目的探讨芳香化酶抑制剂在妇科内分泌治疗中的应用效果。方法选取本院2009年8月-2012年10月收治的74例妇科内分泌患者,针对所有患者的临床资料及实际情况进行分析．并对患者采用芳香化酶抑制剂进行治疗,主要包括依西美坦、阿那曲唑及来曲唑,评估患者的治疗效果。结果74例患者中,基本治愈39例．显效21例,好转9例,无效5例,治疗总有效率为93．2％;无效的5例患者主要是由于其心理因素影响．与医护人员的配合度不高所致。结论临床上应用芳香化酶抑制剂治疗妇科内分泌疾病的效果较为显著,对于促进患者病情的改善及生活质量提高具有重要意义,值得在临床推广应用。     

乳腺癌新辅助内分泌治疗进展

1概述 自1896年Beatson首次揭示了乳腺癌与卵巢内分泌功能之间的密切关系[1],到抗雌激素药物他莫苷芬（TAM）的临床广泛应用已有百年历史,内分泌治疗乳腺癌的价值已越来越被人们所认识和接受。     

Current status of gene therapy for muscle diseases

The progress made in vector technology and preclinical evaluation of molecular and gene therapy for inherited muscle diseases led to initiation of the first clinical trials using plasmid and adeno-associated virus vectors, as well as antisense oligonucleotides. The scope of this review is to discuss the current status of gene therapy for muscular dystrophy and to highlight recent advances in viral, cell-based as well as molecular therapies.     

Gene therapy of benign gynecological diseases

Gene therapy is the introduction of genetic material into patient's cells to achieve therapeutic benefit. Advances in molecular biology techniques and better understanding of disease pathogenesis have validated the use of a variety of genes as potential molecular targets for gene therapy based approaches. Gene therapy strategies include: mutation compensation of dysregulated genes; replacement of defective tumor-suppressor genes; inactivation of oncogenes; introduction of suicide genes; immunogenic therapy and antiangiogenesis based approaches. Preclinical studies of gene therapy for various gynecological disorders have not only shown to be feasible, but also showed promising results in diseases such as uterine leiomyomas and endometriosis. In recent years, significant improvement in gene transfer technology has led to the development of targetable vectors, which have fewer side-effects without compromising their efficacy. This review provides an update on developing gene therapy approaches to treat common gynecological diseases such as uterine leiomyoma and endometriosis.     

糖尿病药物治疗的现状及药物研究进展

糖尿病是由多种病因引起的、以慢性高血糖为特征的代谢性疾病。现阶段糖尿病的临床药物治疗主要有胰岛素促泌剂、胰岛素增敏剂、减少糖来源类药物、胰岛素及胰岛素类似物以及新型降糖药物。目前针对新靶点及用药新方式的糖尿病治疗药物研究迅速。本文就糖尿病药物治疗的现状和药物研究新进展情况进行概述。     

Current status of antiretroviral therapy

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.     

Current status of antiretroviral therapy

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.     

Hyperthyroidism. Current drug therapy

The choice of treatment for hyperthyroidism should be preceded by considering: (a) whether the diagnosis is correct; (b) the severity of the disorder; (c) the cause of the thyroid hormone excess; (d) factors such as patient age, size of goitre, associated diseases, previous treatment, and (e) patient preference. If hyperthyroidism appears to be severe, a judgement based on clinical rather than biochemical features, there is generally no safe alternative to the initial use of a drug from the thioamide thioureylene group (carbimazole, methimazole or propylthiouracil) to make the patient euthyroid as rapidly as possible. There are numerous different schedules for the use of these drugs, alone or in conjunction with surgery, radioactive iodine, or drugs such as beta-blocking agents, iodide or thyroxine. Patients can be made euthyroid with reasonable certainty, but an underlying abnormality often remains. The patient's understanding of the natural history of his or her condition is crucial in achieving adequate follow-up.     

肾脏疾病的精准药物治疗

精准药物治疗是精准医学的重要内容,是基于患者个体特征制定治疗方案的个性化医疗模式。肾脏疾病种类繁多,发病机制复杂,患者个体差异大,精准治疗尤为重要。肾脏疾病精准治疗的目标是研究发现与治疗相关的生物标志物,以及通过药物相关基因或特定目标基因进行治疗干预。目前,肾脏疾病精准药物治疗在生物标志物、药物遗传学等方面取得了一定进展,本文主要就相关研究进展进行综述。